EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells

Genes and Development

Volumn 24, Issue 9, 2010, Pages 916-932

  Riggi, Nicolò ^a   Suvà, Mario Luca ^a   De Vito, Claudio ^a   Provero, Paolo ^b   Stehle, Jean Christophe ^a   Baumer, Karine ^a   Cironi, Luisa ^a   Janiszewska, Michalina ^a   Petricevic, Tanja ^a   Suvà, Domizio ^c   Tercier, Stéphane ^a   Joseph, Jean Marc ^a   Guillou, Louis ^a   Stamenkovic, Ivan ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Cancer stem cells; Ewing sarcoma; Mesenchymal stem cells; miRNA145; Reprogramming; SOX2

Indexed keywords

MICRORNA; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

ADOLESCENT; ANIMAL CELL; ARTICLE; CANCER STEM CELL; CARCINOGENICITY; CELL DIFFERENTIATION; CELL MATURATION; CELL SUBPOPULATION; CHILD; EMBRYONIC STEM CELL; EWING SARCOMA; FEEDBACK SYSTEM; FUSION GENE; GENE EXPRESSION; GENE REPRESSION; GENE TARGETING; HUMAN; IN VITRO STUDY; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHILD; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MESENCHYMAL STEM CELLS; MICRORNAS; NEOPLASTIC STEM CELLS; NUCLEAR REPROGRAMMING; OCTAMER TRANSCRIPTION FACTOR-3; PHENOTYPE; PROTO-ONCOGENE PROTEIN C-FLI-1; RNA-BINDING PROTEIN EWS; SARCOMA, EWING'S; SOXB1 TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 77951785861     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.1899710     Document Type: Article

References (51)

1. Argiropoulos B, Yung E, Humphries RK. 2007. Unraveling the crucial roles of Meis1 in leukemogenesis and normal hematopoiesis. Genes & Dev 21: 2845-2849. (Pubitemid 350133432)
2. Baird K, Davis S, Antonescu CR, Harper UL, Walker RL, Chen Y, Glatfelter AA, Duray PH, Meltzer PS. 2005. Gene expression profiling of human sarcomas: Insights into sarcoma biology. Cancer Res 65: 9226-9235. (Pubitemid 41507988)
3. Banito A, Rashid ST, Acosta JC, Li S, Pereira CF, Geti I, Pinho S, Silva JC, Azuara V, Walsh M, et al. 2009. Senescence impairs successful reprogramming to pluripotent stem cells. Genes & Dev 23: 2134-2139.
4. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, Kim SY, Wardwell L, Tamayo P, Gat-Viks I, et al. 2009. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 41: 1238-1242.
5. Breitling R, Armengaud P, Amtmann A, Herzyk P. 2004. Rank products: A simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett 573: 83-92. (Pubitemid 39141040)
6. Carrillo J, Garcia-Aragoncillo E, Azorin D, Agra N, Sastre A, Gonzalez-Mediero I, Garcia-Miguel P, Pestana A, Gallego S, Segura D, et al. 2007. Cholecystokinin down-regulation by RNA interference impairs Ewing tumor growth. Clin Cancer Res 13: 2429-2440. (Pubitemid 46698594)
7. Chivukula RR, Mendell JT. 2009. Abate and switch: miR-145 in stem cell differentiation. Cell 137: 606-608.
8. Cironi L, Riggi N, Provero P, Wolf N, Suva ML, Suva D, Kindler V, Stamenkovic I. 2008. IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells. PLoS One 3: e2634. doi: 10.1371/journal.pone.0002634.
9. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. 2006. Cancer stem cells - Perspectives on current status and future directions: AACR Workshop on Cancer Stem Cells. Cancer Res 66: 9339-9344. (Pubitemid 44623625)
10. Dauphinot L, De Oliveira C, Melot T, Sevenet N, Thomas V, Weissman BE, Delattre O. 2001. Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2 and c-Myc expression. Oncogene 20: 3258-3265. (Pubitemid 32553678)
11. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, de Jong P, Rouleau G, et al. 1992. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359: 162-165.
12. Deneen B, Denny CT. 2001. Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation. Oncogene 20: 6731-6741. (Pubitemid 33020602)
13. Dirks WG, Fahnrich S, Lis Y, Becker E, MacLeod RA, Drexler HG. 2002. Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines. Int J Cancer 100: 49-56. (Pubitemid 34602064)
14. Ellis P, Fagan BM, Magness ST, Hutton S, Taranova O, Hayashi S, McMahon A, Rao M, Pevny L. 2004. SOX2, a persistent marker for multipotential neural stem cells derived from embryonic stem cells, the embryo or the adult. Dev Neurosci 26: 148-165. (Pubitemid 40867972)
15. Feng B, Ng JH, Heng JC, Ng HH. 2009. Molecules that promote or enhance reprogramming of somatic cells to induced pluripotent stem cells. Cell Stem Cell 4: 301-312.
16. Foell JL, Hesse M, Volkmer I, Schmiedel BJ, Neumann I, Staege MS. 2008. Membrane-associated phospholipase A1 β (LIPI) is an Ewing tumour-associated cancer/testis antigen. Pediatr Blood Cancer 51: 228-234. (Pubitemid 351877042)
17. Fong H, Hohenstein KA, Donovan PJ. 2008. Regulation of self-renewal and pluripotency by Sox2 in human embryonic stem cells. Stem Cells 26: 1931-1938.
18. Graham V, Khudyakov J, Ellis P, Pevny L. 2003. SOX2 functions to maintain neural progenitor identity. Neuron 39: 749-765. (Pubitemid 37088088)
19. Helman LJ, Meltzer P. 2003. Mechanisms of sarcoma development. Nat Rev Cancer 3: 685-694.
20. Hong F, Breitling R, McEntee CW, Wittner BS, Nemhauser JL, Chory J. 2006. RankProd: A bioconductor package for detecting differentially expressed genes in meta-analysis. Bioinformatics 22: 2825-2827. (Pubitemid 44742407)
21. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. 2003. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
22. Jaenisch R, Young R. 2008. Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell 132: 567-582. (Pubitemid 351253686)
23. Janne PA, Gray N, Settleman J. 2009. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 8: 709-723.
24. Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G, et al. 2008. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455: 967-970.
25. Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A, Wahl GM, Belmonte JC. 2009. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 460: 1140-1144.
26. Lagadec C, Meignan S, Adriaenssens E, Foveau B, Vanhecke E, Romon R, Toillon RA, Oxombre B, Hondermarck H, Le Bourhis X. 2009. TrkA overexpression enhances growth and metastasis of breast cancer cells. Oncogene 28: 1960-1970.
27. Lee J, Rhee BK, Bae GY, Han YM, Kim J. 2005. Stimulation of Oct-4 activity by Ewing's sarcoma protein. Stem Cells 23: 738-751. (Pubitemid 40791789)
28. Lessnick SL, Dacwag CS, Golub TR. 2002. The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell 1: 393-401.
29. Liu Y, Clem B, Zuba-Surma EK, El-Naggar S, Telang S, Jenson AB, Wang Y, Shao H, Ratajczak MZ, Chesney J, et al. 2009. Mouse fibroblasts lacking RB1 function form spheres and undergo reprogramming to a cancer stem cell phenotype. Cell Stem Cell 4: 336-347.
30. Maherali N, Hochedlinger K. 2008. Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell 3: 595-605.
31. Marion RM, Strati K, Li H, Murga M, Blanco R, Ortega S, Fernandez-Capetillo O, Serrano M, Blasco MA. 2009. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 460: 1149-1153.
32. Montagut C, Settleman J. 2009. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 283: 125-134.
33. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, Laquaglia MJ, Sennett R, Lynch JE, Perri P, et al. 2008. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455: 930-935.
34. Ordonez JL, Osuna D, Herrero D, de Alava E, Madoz-Gurpide J. 2009. Advances in Ewing's sarcoma research: Where are we now and what lies ahead? Cancer Res 69: 7140-7150.
35. Peter M, Gilbert E, Delattre O. 2001. A multiplex real-time PCR assay for the detection of gene fusions observed in solid tumors. Lab Invest 81: 905-912. (Pubitemid 32553411)
36. Reichardt LF. 2006. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci 361: 1545-1564.
37. Riggi N, Stamenkovic I. 2007. The biology of Ewing sarcoma. Cancer Lett 254: 1-10.
38. Riggi N, Cironi L, Provero P, Suva ML, Kaloulis K, Garcia-Echeverria C, Hoffmann F, Trumpp A, Stamenkovic I. 2005. Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res 65: 11459-11468. (Pubitemid 41821703)
39. Riggi N, Cironi L, Suva ML, Stamenkovic I. 2007. Sarcomas: Genetics, signalling, and cellular origins. Part 1: The fellowship of TET. J Pathol 213: 4-20. (Pubitemid 47354561)
40. Riggi N, Suva ML, Suva D, Cironi L, Provero P, Tercier S, Joseph JM, Stehle JC, Baumer K, Kindler V, et al. 2008. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells. Cancer Res 68: 2176-2185. (Pubitemid 351521790)
41. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. 2003. Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828. (Pubitemid 37187480)
42. Staege MS, Hutter C, Neumann I, Foja S, Hattenhorst UE, Hansen G, Afar D, Burdach SE. 2004. DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. Cancer Res 64: 8213-8221. (Pubitemid 39491758)
43. Suva D, Garavaglia G, Menetrey J, Chapuis B, Hoffmeyer P, Bernheim L, Kindler V. 2004. Non-hematopoietic human bone marrow contains long-lasting, pluripotential mesenchymal stem cells. J Cell Physiol 198: 110-118. (Pubitemid 38120971)
44. Suva D, Passweg J, Arnaudeau S, Hoffmeyer P, Kindler V. 2008. In vitro activated human T lymphocytes very efficiently attach to allogenic multipotent mesenchymal stromal cells and transmigrate under them. J Cell Physiol 214: 588-594.
45. Suva ML, Riggi N, Stehle JC, Baumer K, Tercier S, Joseph JM, Suva D, Clement V, Provero P, Cironi L, et al. 2009. Identification of cancer stem cells in Ewing's sarcoma. Cancer Res 69: 1776-1781.
46. Takashima Y, Era T, Nakao K, Kondo S, Kasuga M, Smith AG, Nishikawa S. 2007. Neuroepithelial cells supply an initial transient wave of MSC differentiation. Cell 129: 1377-1388. (Pubitemid 46970707)
47. Thomas S, Thomas M, Wincker P, Babarit C, Xu P, Speer MC, Munnich A, Lyonnet S, Vekemans M, Etchevers HC. 2008. Human neural crest cells display molecular and phenotypic hallmarks of stem cells. Hum Mol Genet 17: 3411-3425.
48. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O. 2007. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 11: 421-429. (Pubitemid 46680428)
49. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G, Medema JP, et al. 2007. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1: 389-402. (Pubitemid 47506537)
50. Welford SM, Hebert SP, Deneen B, Arvand A, Denny CT. 2001. DNA binding domain-independent pathways are involved in EWS/FLI1-mediated oncogenesis. J Biol Chem 276: 41977-41984. (Pubitemid 37371099)
51. Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS. 2009. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 137: 647-658.